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IntroductIon
Acute lymphoblastic leukemia (ALL) is the most frequent 
childhood cancer. Whereas ∼90% of pediatric ALL patients 
can be cured with current therapies, the prognosis for adult 
patients and children with relapsed disease is poor (Hunger and 
Mullighan, 2015). Over the last decade, our understanding of 
the genetic basis of B lineage ALL (B-ALL) pathogenesis and 
treatment response has been revolutionized by high-resolution 
genomic and transcriptional profiling of large patient cohorts 
(Roberts and Mullighan, 2015). These studies reveal that a ma-
jority of patients with B-ALL harbor somatic mutations or 
focal deletions that disable genes encoding lymphoid transcrip-
tion factors, including EBF1, PAX5, and IKZF1 (Kuiper et al., 
2007; Mullighan et al., 2007; Roberts and Mullighan, 2015).
Approximately 5% of pediatric B-ALL patients have 
disease harboring the t(9;22) translocation, forming what is 
commonly termed the Philadelphia (Ph) chromosome and 
resulting in expression of the oncogenic BCR-ABL1 fusion 
kinase. A novel disease subtype was recently defined based 
on a gene expression profile similar to Ph+ disease, termed 
Ph-like or BCR-ABL1-like B-ALL (Den Boer et al., 
2009; Mullighan et al., 2009). The Ph+ and Ph-like dis-
ease subtypes have relatively high relapse rates and poor 
prognosis, and together comprise ∼15% of pediatric and 
∼50% of adult B-ALL cases (Roberts et al., 2012, 2014; 
van der Veer et al., 2013). Somatic genetic alterations in 
IKZF1, which encodes the zinc finger transcription factor 
IKA ROS, occur in 50–70% of Ph+ and Ph-like B-ALL 
cases (Mullighan et al., 2008a, 2009; Den Boer et al., 2009; 
Roberts et al., 2012, 2014; van der Veer et al., 2013, 2014; 
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Churchman et al., 2015). These lesions commonly involve 
monoallelic loss of IKZF1 or deletion of internal exons, 
causing expression of dominant-negative protein iso-
forms, but also include deleterious point mutations and 
rare bi-allelic deletions. Although loss of normal IKA ROS 
function clearly cooperates with BCR-ABL1 or other 
kinase-activating lesions during Ph+ and Ph-like B-ALL 
pathogenesis, the specific mechanistic basis for this genetic 
interaction remains unknown.
IKZF1 is unique among B-ALL transcription factor 
tumor suppressors in that its mutation or deletion is associ-
ated with adverse prognosis across multiple patient cohorts 
(Iacobucci et al., 2009; Martinelli et al., 2009; Mullighan 
et al., 2009; Kuiper et al., 2010; van der Veer et al., 2013). 
Furthermore, genomic studies of paired diagnosis and re-
lapsed B-ALL samples demonstrate high rates of acquired 
IKZF1 alterations or positive selection of IKZF1-deficient 
subclones at relapse (Mullighan et al., 2008b; Yang et al., 
2008; Kuiper et al., 2010; Dupuis et al., 2013; Krentz et al., 
2013), and IKZF1 lesions also occur during progression 
from chronic phase CML to therapy-resistant lymphoid 
blast crisis disease (Mullighan et al., 2008a). IKZF1 dele-
tions are also associated with high levels of residual disease 
after remission-induction therapy (Mullighan et al., 2009; 
Waanders et al., 2011; van der Veer et al., 2013). These stud-
ies suggest a role for IKZF1 loss in therapy resistance that 
may contribute to the poor treatment responses of Ph+ and 
Ph-like disease. Consistent with this idea, IKZF1 lesions 
independently predict high rates of relapse and decreased 
survival within Ph+ or Ph-like B-ALL cohorts after standard 
therapy (Martinelli et al., 2009; Mullighan et al., 2009; van 
der Veer et al., 2013; Roberts et al., 2014), and its loss is 
also associated with clinical resistance to the BCR-ABL1 
inhibitor imatinib (van der Veer et al., 2014). Together, these 
studies point to a central role for IKZF1 deletions in B-ALL 
progression and treatment resistance.
Mouse models have identified critical Ikaros func-
tions in lymphocyte development. Ikaros is required for 
normal function and lineage commitment of hematopoi-
etic stem and progenitor cells (Nichogiannopoulou et al., 
1999; Yoshida et al., 2006). Germline Ikaros-deficient mice 
have no B cells and defective T and myeloid lineage devel-
opment (Wang et al., 1996), and conditional Ikaros inacti-
vation in B lineage progenitors arrests their differentiation 
(Heizmann et al., 2013; Joshi et al., 2014; Schwickert et al., 
2014). Hypomorphic Ikaros alleles promote development 
of aggressive T-ALL (Winandy et al., 1995; Dumortier 
et al., 2006) and also accelerate disease in models of Ph+ 
B-ALL (Virely et al., 2010; Schjerven et al., 2013; Church-
man et al., 2015), verifying a conserved tumor suppressor 
function. Several recent studies have identified Ikaros- 
regulated genes through expression profiling of Ikaros- 
deficient B cell progenitors and B-ALL cells (Fer-
reirós-Vidal et al., 2013; Heizmann et al., 2013; Schjer-
ven et al., 2013; Joshi et al., 2014; Schwickert et al., 2014; 
Churchman et al., 2015), linking their differentiation arrest 
to perturbed IL-7 and pre–BCR signaling (Heizmann et 
al., 2013; Schwickert et al., 2014). Ikaros-deficient B cell 
progenitors and B-ALL cells also show increased integrin 
signaling and adhesion to stromal cells (Joshi et al., 2014; 
Schwickert et al., 2014; Churchman et al., 2015). Although 
targeting these adhesion phenotypes attenuates prolifera-
tion of Ikaros-deficient cells (Joshi et al., 2014; Churchman 
et al., 2015), their relative role in B-ALL pathogenesis and 
treatment response is unclear.
Understanding the molecular basis of how IKZF1 de-
letions drive B-ALL development and therapy resistance can 
inform the development of improved treatments. Using a 
novel transgenic mouse model of Ikaros-low, BCR-ABL1+ 
B-ALL, we demonstrate that Ikaros suppression not only 
accelerates leukemia development but is subsequently re-
quired for its maintenance. Through integrated transcrip-
tional profiling of multiple murine B-ALL models and 
human B-ALL patient cohorts, we identify several high con-
fidence, conserved IKA ROS-repressed genes. These include 
EMP1, encoding a known mediator of B-ALL treatment re-
sistance, and CTN ND1, for which we demonstrate a novel 
role in B-ALL maintenance.
rESuLtS
Ikaros knockdown accelerates onset of Bcr-ABL1+ B-ALL
To generate a mouse model of high-risk, BCR-ABL1+, IKZF1 
mutant human B-ALL, we adopted a well-characterized 
BCR-ABL1P190 transgenic mouse strain that succumbs to 
B-ALL after 3–6 mo (Heisterkamp et al., 1990). To allow 
reversible control of endogenous Ikaros expression in estab-
lished B-ALL in vivo, we first generated a novel transgenic 
mouse strain where a tetracycline (tet)-regulated (TRE) pro-
moter targeted to the type I collagen locus controls coex-
pression of GFP, along with an effective microRNA-based 
short hairpin RNA (shRNA) targeting murine Ikaros. We 
crossed these TRE-GFP-shIkaros mice to Vav-tTA trans-
genic mice, which express the tTA (tet-off) transactivator 
across the hematopoietic system (Kim et al., 2007; Takigu-
chi et al., 2013). Bi-transgenic animals succumbed to a GFP+ 
T lineage leukemia similar to our previous findings (Wit-
kowski et al., 2015), verifying effective Ikaros knockdown in 
vivo (unpublished data).
Using a mating strategy that produces mice of uniform 
strain background (Fig. S1, A and B), we generated a cohort 
of BCR-ABL1P190;Vav-tTA;TRE-GFP-shIkaros triple trans-
genic mice and BCR-ABL1P190;Vav-tTA bi-transgenic litter-
mate controls. Triple transgenic mice succumbed to B-ALL 
of similar immunophenotype to BCR-ABL1P190 control dis-
ease, but with approximately half the latency (Fig. 1, A and 
B; median survival 36 d versus 80 d; P < 0.0001, log-rank 
test). Leukemias arising in triple transgenic mice (hereafter 
termed Ikaros-kd B-ALL) were uniformly GFP+, verify-
ing that Ikaros knockdown contributes to accelerated leu-
kemogenesis (Fig. 1 B).
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In parallel, using previously established protocols (Li et 
al., 1999), we generated an additional B-ALL model through 
retroviral expression of BCR-ABL1P190 in bone marrow cells 
that were then used to reconstitute lethally irradiated recipi-
ent mice. To allow reversible Ikaros knockdown, we infected 
bone marrow cells from TREtight-GFP-shIkaros.4056 
or control TREtight-GFP-shRenilla.713 transgenic mice 
(Witkowski et al., 2015) with retroviral vectors stably ex-
pressing BCR-ABL1P190 and tTA (Fig. 1 C). Recipients of 
co-transduced TREtight-GFP-shIkaros cells had signifi-
cantly accelerated onset of a CD19+IgM– B-ALL compared 
with TREtight-GFP-shRenilla controls (median survival 17 
d and 22 d, respectively; P < 0.0001), and again this Ikaros-kd 
disease was GFP+ (Fig. 1, D and E). Hence, transgenic shR-
NA-mediated knockdown of Ikaros cooperates with trans-
genic or retroviral expression of the BCR-ABL1P190 fusion 
oncogene to recapitulate the genetic interaction between 
IKA ROS hypomorphism and BCR-ABL1 previously ob-
served in human B-ALL and in germline Ikaros mutant 
mouse models (Mullighan et al., 2008a; Virely et al., 2010; 
Schjerven et al., 2013).
Ikaros knockdown is critical for 
Bcr-ABL1+ B-ALL maintenance
To address whether ongoing Ikaros suppression is required for 
B-ALL maintenance in vivo, we transplanted leukemia cells 
from several independent primary BCR-ABL1P190;Vav-tTA 
control or BCR-ABL1P190;Vav-tTA;TRE-GFP-shIkaros 
Ikaros-kd tumors (expressing the surface marker CD45.2) into 
cohorts of Rag1−/− CD45.1+ recipient mice. All untreated 
transplant recipient mice rapidly developed disease and be-
come moribund within 2–4 wk (Fig. 2 A). Upon disease onset 
(donor-derived CD45.2+, CD19+IgM– cells exceeding ∼5% 
of peripheral leukocytes), subsets of recipients were given food 
supplemented with the tetracycline analogue doxycycline 
(Dox). In mice bearing Ikaros-kd B-ALL, 3 d of Dox treat-
ment uniformly diminished GFP expression and increased 
Ikaros protein expression in leukemia cells in vivo, consis-
tent with shutdown of tTA activity and loss of Ikaros shRNA 
(Fig. 2, B–D). Acute Dox treatment did not affect BCR-ABL1 
mRNA expression or phosphorylation of the canonical BCR-
ABL1 substrate STAT5 in B-ALL cells in vivo (Fig. S1, C–F). 
Although Dox treatment of mice bearing control B-ALL had 
Figure 1. reversible Ikaros knockdown promotes Bcr-ABL1+ B cell leukemogenesis. (A) Kaplan-Meier survival analysis of BCR-ABL1P190;Vav-tTA;TRE-
GFP-shIkaros mice (n = 19) and BCR-ABL1P190;Vav-tTA control mice (n = 17). Median survival 36 d versus 80 d, respectively; P < 0.0001, Log-rank (Man-
tel-Cox) test. (B) Flow cytometry of CD19/IgM and CD24/CD43 immunophenotype of splenocytes isolated from representative primary leukemic mice, and 
GFP expression of CD19+IgM– cells. (C) Schematic of adoptive transfer approach to generate BCR/ABL1+ B-ALL accelerated by reversible Ikaros knockdown. 
TRE-GFP-shIkaros or TRE-GFP-shRenilla transgenic bone marrow cells are co-transduced with MSCV vectors expressing BCR/ABL1 and tTA, and transplanted 
into lethally irradiated recipient mice. (D) Kaplan-Meier survival analysis of mice transplanted with TRE-GFP-shIkaros (n = 17) or control TRE-GFP-shRenilla 
(n = 16) cells infected as in C. Median survival 17 d versus 22 d, respectively; P < 0.0001, log-rank test. (E) Flow cytometry of CD19, IgM, and GFP expression 
of splenocytes isolated from representative leukemic primary recipient mice transplanted with infected TRE-GFP-shIkaros transgenic bone marrow cells.
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no effect (Fig. S1, G–I), sustained Dox treatment of leukemic 
Ikaros-kd recipient mice resulted in significantly enhanced 
survival (median survival 19 d for untreated versus 113 d for 
Dox-treated mice; P < 0.0001; Fig. 2 A). After 2–3 wk of Dox 
treatment, B-ALL cells were almost completely cleared from 
the peripheral blood and spleen, and the remaining CD45.2+ 
cells had acquired IgM expression consistent with B lineage 
differentiation (Fig. 2, E–G). Of note, 2 Ikaros-kd B-ALL re-
cipient mice remained disease-free 1 yr after Dox treatment 
commenced, suggesting that Ikaros restoration in established 
B-ALL can be curative in this leukemia transplant model 
(Fig.  2 A). Approximately half (6/16) of Dox-treated mice 
eventually relapsed with a GFP–CD45.2+CD19+IgM– B-ALL 
similar to the original disease (Fig. S2 A; described further 
below). Together these data demonstrate a critical role for 
Ikaros suppression in B-ALL maintenance despite the ongo-
ing expression of oncogenic BCR-ABL1, providing rationale 
for restoring the Ikaros-regulated gene expression program as 
a potential therapeutic strategy in this context.
Ikaros-regulated genes in murine Bcr-ABL1+ B-ALL
Having demonstrated that Ikaros suppression accelerates 
leukemogenesis and its restoration triggers dramatic dis-
ease regression, we used RNA sequencing (RNA-seq) to 
define the Ikaros-regulated transcriptome in these con-
texts. To identify transcriptional changes associated with 
accelerated onset of BCR-ABL1+ B-ALL caused by 
Ikaros knockdown, we compared expression profiles of 
B-ALL cells isolated by FACS from the spleens of re-
cipient mice bearing independent primary Ikaros-kd 
leukemias (four BCR-ABL1P190;Vav-tTA;TRE-GFP- 
shIkaros leukemias and three TRE-GFP-shIkaros/retroviral 
BCR-ABL1P190 leukemias) to independent primary con-
trol leukemias (three BCR-ABL1P190;Vav-tTA bi-transgenic 
leukemias and one TRE-GFP-shRenilla/retroviral BCR-
ABL1P190 leukemia). This identified 758 significantly up-reg-
ulated genes and 561 significantly down-regulated genes 
in Ikaros-kd B-ALL relative to control B-ALL at 5% false 
discovery rate (FDR). These were called Acceleration genes 
(Fig. 3 A and Table S1).
To identify dynamic transcriptional changes accom-
panying acute Ikaros restoration in established B-ALL in 
vivo, we compared the expression profile of flow-sorted 
CD19+IgM– B-ALL cells harvested from the spleens of several 
mice bearing independent primary Ikaros-kd leukemias (four 
BCR-ABL1P190;Vav-tTA;TRE-GFP-shIkaros leukemias and 
three TRE-GFP-shIkaros/retroviral BCR-ABL1P190 leuke-
mias) that were either untreated (GFPhi cells) or after 3-d in 
vivo Dox treatment (GFPmid cells, immunophenotypically 
indistinguishable from untreated). Endogenous Ikaros resto-
ration in B-ALL in vivo led to induction of 1,074 genes and 
repression of 1,294 genes at 5% FDR, termed Restoration 
genes (Fig. 3 B and Table S2).
We hypothesized that the global gene expression pro-
file associated with Ikaros knockdown in steady-state B-ALL 
may be partially reversed upon acute Ikaros restoration. In-
deed, a genuine association (genas) analysis, which estimates 
the underlying correlation between expression profiles cor-
recting for technical features, confirmed a strong inverse cor-
relation between global Acceleration and Restoration gene 
expression changes (correlation = –0.67; P < 10−16; Fig. 3 C). 
Comparing both experiments (5% FDR) enabled classifica-
tion of Ikaros-regulated genes into two groups: (1) 223 genes 
with reduced expression in Ikaros-kd B-ALL relative to con-
trol B-ALL that are also up-regulated upon Ikaros restoration, 
designated Ikaros-activated genes; and (2) 326 genes with 
elevated expression in Ikaros-kd B-ALL relative to control 
B-ALL that are also repressed upon Ikaros restoration, des-
ignated Ikaros-repressed genes (Fig.  3 C and Table S3). Of 
the 567 total genes with significant differential expression in 
both experiments, only 18 (3%) showed discordant expres-
sion (Fig. 3 C), suggesting this strategy can effectively iden-
tify Ikaros-regulated genes in BCR-ABL1+ B-ALL in vivo. 
Roast gene set analysis comparing Ikaros-regulated genes 
to transcriptional changes occurring during normal murine 
B cell development in the bone marrow (Hoffmann et al., 
2002) indicated that although Ikaros-kd leukemias are im-
munophenotypically similar to control leukemias driven by 
BCR-ABL1 alone, transcriptionally they appear arrested at 
an earlier progenitor stage, and this differentiation block is 
partially released upon acute Ikaros restoration (Fig. S1 J). 
Consistent with previous studies implicating Ikaros in cellular 
adhesion (Joshi et al., 2014; Schwickert et al., 2014; Church-
man et al., 2015), gene ontology and KEGG pathway analysis 
indicated that Ikaros-repressed genes were significantly en-
riched for genes involved in cell–cell junctions/focal adhe-
sions (Tables S4 and S5).
Identifying conserved transcriptional targets of Ikaros 
in human and mouse B-ALL
Recent RNA-seq of large human B-ALL sample cohorts has 
uncovered the transcriptional landscape of different B-ALL 
subtypes (Roberts and Mullighan, 2015). To identify transcrip-
tomic changes associated with IKZF1 disruption in B-ALL, 
we examined a recently described cohort of 289 patients, in-
cluding 252 patients with known IKZF1 mutation status (US 
cohort: St Jude Total studies, COG P9906, AALL0232, and 
adult ALL cohorts; Roberts et al., 2014). This cohort com-
prises multiple disease subtypes, but contains a high proportion 
(53%) of Ph+ and Ph-like cases with known poor outcome 
that are also enriched for IKZF1 alterations (Fig. S3 A; Rob-
erts et al., 2014). Analysis of RNA-seq data from this cohort 
identified 661 up-regulated genes and 1,249 down-regulated 
genes (1% FDR) in 103 IKZF1 mutated/deleted (IKZF-
1mut/del) samples when compared with 144 IKZF1 wild-type 
(IKZF1wt) samples, designated IKA ROS-repressed and IKA 
ROS-activated genes, respectively (Fig. 3, D and E; and Table 
S6). We similarly analyzed microarray expression data from an 
independent cohort of 573 patients (DCOG/COA LL cohort: 
Dutch ALL-8, -9, and -10, and German COA LL-97 and -03–
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treated patients), including 139 cases with IKZF1 deletions 
and 371 cases without IKZF1 deletions (Den Boer et al., 2009; 
van der Veer et al., 2013). This cohort comprises major B-ALL 
subtypes at representative proportions, including 20% Ph+/
BCR-ABL1-like cases (Fig. S4 A). Our analysis identified 386 
IKA ROS-repressed and 525 IKA ROS-activated genes at 1% 
FDR (Fig. 3, D and E; and Table S7). Combined analysis iden-
tified 156 IKA ROS-repressed genes and 278 IKA ROS-acti-
Figure 2. Ikaros suppression is critical for maintenance of Ikaros-kd B-ALL. (A) Kaplan-Meier survival analysis of Ikaros-kd B-ALL transplant recip-
ient mice (six independent primary BCR-ABL1;Vav-tTA;TRE-GFP-shIkaros leukemias, two to three recipients per condition) either untreated or Dox-treated 
upon disease establishment. Median survival 19 d for untreated versus 113 d for Dox treated; P < 0.0001, log-rank test. Censored events represent deaths 
unrelated to leukemia, including fighting and infection. (B) GFP expression of splenocytes from representative Ikaros-kd B-ALL–recipient mice that were 
untreated (d0) or Dox treated as indicated upon leukemia onset. (C) Western blot of Ikaros expression in control or Ikaros-kd B-ALL cells isolated from rep-
resentative leukemic mice that were untreated or Dox treated as indicated. The Ikaros protein isoforms Ik1 and Ik2 are indicated. Actin is a loading control. 
(D) Western blot of Ikaros protein expression in Ikaros-kd B-ALL cells isolated from representative leukemic recipient mice that were untreated or Dox 
treated as indicated. (E) Flow cytometry of CD19 and IgM in CD45.2+ (donor-derived) peripheral blood cells from representative untreated (upper panels) or 
Dox-treated (lower panels) leukemic Ikaros-kd B-ALL transplant recipient mice. (F) Spleen histology of representative Ikaros-low B-ALL transplant recipient 
mice that were untreated or Dox treated for 14 d at disease onset, with arrows indicating follicular structures. (G) Flow cytometry of CD19 and IgM in 
CD45.2+ splenocytes from representative Ikaros-kd B-ALL transplant recipient mice with Dox treatments indicated.
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vated genes common to the US and DCOG/COA LL B-ALL 
cohorts (Fig. 3, D and E; and Table S8).
To identify conserved Ikaros target genes in B-ALL across 
species, we compared human common IKA ROS-repressed 
and IKA ROS-activated genes (1% FDR) with murine 
Ikaros-repressed and -activated genes (relaxing the threshold 
to 10% FDR to increase cross-species overlap). This stringent 
approach yielded nine conserved IKA ROS-repressed genes 
and four conserved IKA ROS-activated genes (Fig. 3, D and E).
dynamic, conserved IKA roS-regulated genes are 
enriched for IKA roS binding
To investigate whether our high-confidence IKA ROS- 
regulated genes were directly bound by IKA ROS, we ana-
Figure 3. Identification of conserved IKA roS-regulated genes in Bcr-ABL1+ B-ALL. (A) MA plot of average RNA-seq expression differences in B-ALL 
cells isolated from mice transplanted with primary Ikaros-kd (n = 7) versus control (n = 4) leukemias, highlighting genes with increased (red) or decreased 
(blue) expression at 5% FDR (Acceleration genes). (B) MA plot as in A for B-ALL cells isolated from mice bearing Ikaros-kd B-ALL (n = 7 independent primary 
leukemias), comparing 3 d Dox-treated mice to untreated mice. Genes with increased (red) or decreased (blue) expression at 5% FDR (Restoration genes) 
are highlighted. (C) Scatterplot of moderated t statistics of expressed genes in the Acceleration and Restoration experiments, highlighting genes that are 
differentially expressed (5% FDR) in both. Ikaros-activated genes are highlighted in orange, Ikaros-repressed genes in green, discordant genes in blue, and 
Ikaros/Ikzf1 and Ctnnd1 in red. (D and E) Venn diagrams of IKA ROS-activated genes (D) and IKA ROS-repressed genes (E) in the US and DCOG/COA LL patient 
cohorts (both 1% FDR) intersected with Ikaros-activated and Ikaros-repressed genes identified in murine B-ALL (10% FDR). Conserved IKA ROS-regulated 
genes are listed. (F) IKA ROS ChIP-seq in human B-ALL cells showing significant binding peaks (gray bars) within and adjacent to the conserved IKA ROS- 
repressed genes CTN ND1, EMP1, and IFI TM3.
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lyzed IKA ROS chromatin immunoprecipitation-sequencing 
(ChIP-seq) data from human B-ALL cells (see Schjerven 
et al. in this issue). Notably, 212 of the 326 Ikaros-repressed 
genes (67%) and 147 of the 223 Ikaros-activated genes (66%) 
identified using our murine B-ALL models (Fig. 3 C) were 
IKA ROS bound, a significant enrichment compared with 
56% binding for other expressed genes (P = 0.0009 and P = 
0.002, respectively, Fisher’s exact test; Table S3). Interestingly, 
all nine conserved IKA ROS-repressed genes were bound by 
IKA ROS (enrichment P = 0.006 relative to other expressed 
genes, Fisher’s exact test), indicating potential direct repres-
sion by IKA ROS in B-ALL (Fig. 3 F).
High expression of the IKA roS-repressed genes ctn nd1, 
EMP1, and IFI tM3 in B-ALL is associated with decreased 
patient event–free survival
Consistent with previous studies (van der Veer et al., 2013; 
Roberts et al., 2014), IKZF1 mutation/deletion is asso-
ciated with poor event–free survival (EFS) in the US pa-
tient cohort (hazard ratio [HR] = 3.21; 95% confidence 
interval [CI] = 2.23–5.83; log rank P = 1.0 × 10−5), and 
the DCOG/COA LL patient cohort (HR = 2.47; 95% CI 
= 1.67–3.63; P = 2.3 × 10−6) we used to identify IKA 
ROS-regulated genes (Fig. 4 A). We reasoned that altered 
expression of conserved IKA ROS-activated and IKA 
ROS-repressed genes may also have prognostic value in 
B-ALL. To address this, we examined EFS in patient co-
horts after dividing them based on IKA ROS-regulated 
gene expression into low (less than median) and high 
(greater than median) groups (Figs. S3, B and C; and S4, 
B and C). Low expression of the conserved IKA ROS- 
activated genes CSF2RB, C1GALT1, and ORAI2 pre-
dicted poor EFS in the DCOG/COA LL cohort; however, 
only ORAI2 was also predictive in the US cohort (Fig. S3, 
B and C; Fig. S4, B and C; and Table 1). High expression 
of six of the nine conserved IKA ROS-repressed genes was 
associated with inferior EFS in both patient cohorts, with 
particularly strong effects observed for CTN ND1, EMP1, 
and IFI TM3 (Fig. 4, B–D; Fig. S3 C; Fig. S4 C; and Tables 
1 and 2). Remarkably, stratifying DCOG/COA LL patients 
by median CTN ND1 expression was a better predictor 
of EFS than IKZF1 deletion status, with high expression 
conferring almost threefold higher risk (Fig. 4, A and B; 
and Table  2). Furthermore, high CTN ND1 expression 
predicted poor outcome even within IKZF1 wild-type 
or IKZF1-deleted subgroups of that cohort, with 5-yr 
EFS <60% for patients with combined IKZF1 deletion 
and high CTN ND1 expression (Fig.  4  E and Table  2). 
High CTN ND1 expression was also associated with in-
ferior EFS within BCR-ABL1+/BCR-ABL1-like or 
non-BCR-ABL1+/BCR-ABL1-like subgroups (Fig. 4 F). 
High EMP1 expression was also associated with decreased 
EFS in IKZF1 wild-type samples in both patient cohorts, 
whereas the predictive value of high IFI TM3 expression 
appeared to depend on an association with IKZF1 deletion 
(Fig. 4, G and H; and Table 2).
comparable deregulation of IKA roS-repressed genes 
in mouse and human B-ALL
The correlation between elevated CTN ND1, EMP1, or IFI 
TM3 expression with poor disease outcome in two indepen-
dent patient cohorts is notable given that they are among the 
most highly expressed of the conserved IKA ROS-regulated 
genes by RNA-seq in the US sample cohort and our mouse 
B-ALL model (Fig. 5, A–C; Fig. S3, B and C; and Fig. S5, A 
and B). Expression of each gene is elevated approximately 
twofold in IKA ROS/Ikaros-disrupted B-ALL in both spe-
cies, and is rapidly normalized upon acute Ikaros restoration 
in Ikaros-kd leukemia (Fig. 5, A–C). Together, these expres-
sion and outcome data implicate EMP1, IFI TM3, and CTN 
ND1, as IKA ROS-repressed genes with potential functional 
importance in B-ALL pathogenesis and therapy response. In-
triguingly, high EMP1 expression has recently been associated 
with poor outcome in B-ALL by promoting resistance to 
glucocorticoids (Ariës et al., 2014). Hence our identification 
of EMP1 as a novel and conserved IKA ROS-repressed gene 
suggests a potential mechanism whereby IKZF1 disruption 
promotes B-ALL treatment resistance.
Also noteworthy among IKA ROS-repressed genes 
was CTN ND1, which encodes the cadherin-associated 
protein P120-catenin. When ranked by significance, CTN 
ND1 was the top IKA ROS-repressed gene in the DCOG/
COA LL patient cohort and among the top 20 such genes 
in the US cohort (Table 1). Ctnnd1 was the most signifi-
cantly repressed gene in the murine B-ALL transcriptome 
upon Ikaros restoration in vivo, and ranked second among 
mouse Ikaros-repressed genes in our combined analysis 
(Table 1; Tables S2 and S3; and Fig. 5 C). Consistent with 
this RNA-seq analysis, we verified that Ikaros restoration 
triggered rapid loss of Ctnnd1 protein in multiple primary 
Ikaros-kd leukemias, with further Ctnnd1 down-regula-
tion upon sustained Dox treatment (Fig.  5  D). Alterna-
tive pre-mRNA splicing produces multiple CTN ND1/
P120-catenin protein isoforms with cell type–specific 
expression and distinct subcellular localizations/functions 
(Schackmann et al., 2013). Examining RNA-seq data in 
mouse and human BCR-ABL+ B-ALL (driven by Ikaros 
knockdown and IKZF1 alteration, respectively) revealed 
that Ctnnd1/CTN ND1 transcripts predominantly include 
exon A but exclude exons B and C (Fig. S5, C–E). These 
mRNA species encode protein isoforms harboring nu-
clear localization signals and lacking nuclear export sig-
nals, suggesting a potential nuclear role for CTN ND1 in 
B-ALL (see Discussion).
Because Ctnnd1 mRNA consistently fell in Ikaros-kd 
leukemia upon Ikaros restoration, its expression rebounded 
to original high levels in multiple independent primary leu-
kemias harvested from mice that relapsed after long-term 
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Dox administration (Fig. S2, B–D). To examine this further, 
we performed RNA-seq of leukemia cells isolated from 
a series of mice bearing representative Ikaros-kd B-ALL 
B027 that were either untreated or acutely Dox treated, or 
after disease relapse after 103 d on Dox. Notably, elevated 
expression of Ctnnd1 and Emp1 at relapse contributed to 
an overall gene expression signature resembling the origi-
nal untreated leukemia (Fig. S2, B–D), raising the possibil-
ity that renewed expression of these genes may contribute 
to the relapse phenotype.
Inducible knockdown of IKA roS-repressed genes  
in Bcr-ABL1+, Ikaros-kd B-ALL
In BCR-ABL1–driven, Ikaros-kd B-ALL, we hypothesized 
that elevated expression of genes such as Ctnnd1, Emp1, and 
Ifitm3 may contribute to accelerated leukemogenesis, and the 
rapid repression of these genes upon acute Ikaros restoration 
may contribute to disease regression. To examine the depen-
dency of Ikaros-kd B-ALL cells on Ctnnd1, Emp1, or Ifitm3, 
we used a novel strategy to generate primary leukemias in 
which endogenous genes can be dynamically inhibited using 
Figure 4. High ctn nd1, EMP1, or IFI tM3 expression predicts poor event-free survival. (A) Event-free survival analysis of US cohort (left) and 
DCOG/COA LL cohort (right) B-ALL patients separated by IKZF1 mutation status as indicated. Log-rank p-values are shown. (B–D) EFS analysis as described 
for A, but separating cohorts based on median expression of (B) CTN ND1, (C) EMP1, and (D) IFI TM3. Expression of each gene across samples (determined 
by RNA-seq for US cohort and microarray for DCOG/COA LL cohort with probeset indicated) are shown in Figs. S3 and S4. (E and F) EFS for DCOG/COA LL 
patients grouped by IKZF1 deletion status (E) or BCR-ABL1+/like subgroup status (F), and then further separated based on median expression of CTN ND1. (G 
and H) EFS for DCOG/COA LL patients grouped by IKZF1 deletion status, and then further separated based on median expression of EMP1 (G) or IFI TM3 (H).
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tet-regulated RNAi. First, we co-infected wild-type bone 
marrow cells with a retroviral BCR-ABL1P190 expression vec-
tor along with a novel vector encoding the tet-on transacti-
vator rtTA3 linked to a stable shRNA targeting mouse Ikaros 
(MSCV-rtTA3-shIkaros; Fig.  6  A). MSCV-rtTA3-shIkaros 
accelerated BCR-ABL1-driven B lineage leukemogenesis 
when compared with bone marrow infected with the BCR-
ABL1 vector alone (Fig. 6 B, median survival 24 d versus 53 
d; P < 0.05, log-rank test), yielding Ikaros-kd leukemias that 
also express rtTA3 (tet-on competent B-ALL).
To inducibly inhibit murine Ctnnd1, Emp1, and Ifitm3 
we cloned effective miR30-based shRNAs into the retroviral 
TRM PV vector (Zuber et al., 2011), which stably expresses 
the GFP derivative Venus and allows tet-inducible coexpres-
sion of a shRNA linked to the fluorescent marker dsRed 
(Fig.  6  A). We infected primary tet-on competent B-ALL 
cells ex vivo with TRM PV vectors targeting Renilla lucif-
erase (negative control), the essential proliferative driver Myc 
(positive control), and two independent shRNAs targeting 
each IKA ROS-repressed gene. Dox treatment induced dsRed 
fluorescence in GFP+ B-ALL cells in vitro and in vivo, and 
we verified depletion of target gene mRNA and protein in 
these cells (Fig. 6, C–E).
ctnnd1 promotes primary Ikaros-kd B-ALL 
growth and viability ex vivo
To assess the role of conserved IKA ROS-repressed genes in 
Ikaros-kd B-ALL maintenance, we plated freshly harvested 
BCR-ABL1-rtTA3-shIkaros B-ALL cells on OP9 stro-
mal cells, which support primary lymphoblast proliferation 
(Nakano et al., 1994). After immediate ex vivo infection of 
two independent primary leukemias with TRM PV vectors 
and growth in Dox medium for 4 d, infected (CD19+G-
FP+mCherry+) cells were mixed at a 1:1 ratio with unin-
Figure 5. regulation of IKA roS-re-
pressed genes in mouse and human B-ALL. 
(A–C) RNA-seq expression (RPKM) of (A) Emp1/
EMP1, (B) Ifitm3/IFI TM3, and (C) Ctnnd1/CTN 
ND1 in control and Ikaros-kd murine B-ALL 
with Dox treatments indicated (left), and the 
in US B-ALL cohort stratified by IKZF1 muta-
tion status (right). P-values from moderated 
Student’s t test. (D) Western blots of Ctnnd1 
and Ikaros protein expression in multiple in-
dependent primary control and Ikaros-kd leu-
kemias. Ikaros-kd samples B038, B027, and 
B031, and control samples B002 and B005 
are transgenic leukemias (Fig.  1 and 2 and 
S1), whereas RV#1044 and #1040 were gen-
erated using the retroviral approach (Fig. S2). 
Actin is a loading control.
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Figure 6. ctnnd1 knockdown compromises growth of Ikaros-kd, Bcr-ABL1+ B-ALL in vitro. (A) Strategy for generating tet-on competent, Ikaros-kd, 
BCR-ABL1+ B-ALL, allowing inducible target gene knockdown. (B) Kaplan-Meier survival analysis of mice reconstituted with infected bone marrow cells as 
shown in A. Recipients of cells co-transduced with MSCV-BCR-ABL1-IRES-Luc2 and MSCV-rtTA3-shIkaros (n = 8) had median survival of 24 d, versus 53 
d for MSCV-BCR-ABL1-IRES-Luc2 alone (n = 4; P = 0.022, log-rank test). (C) Representative dsRed and GFP flow cytometry of tet-on competent Ikaros-kd 
BCR-ABL1+ B-ALL derived from B cells infected with TRM PV vectors as shown in A. Cells were cultured on OP9 stroma and Dox treated as indicated, with 
dsRed marking shRNA expressing cells. (D) RT-qPCR expression of Ctnnd1, Emp1, and Ifitm3 relative to Hprt in ex vivo cultured tet-on competent B-ALL 
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fected (CD19+GFP–mCherry–) cells and plated in Dox for 
an additional 6 d (Fig. 6 F). In this ex vivo competition assay, 
B-ALL cells expressing the positive control Myc shRNA 
were almost completely depleted from the culture (Fig. 6, G 
and H). Cells expressing either of the two effective shRNAs 
targeting Ctnnd1 were also significantly depleted, whereas 
inhibition of Emp1 or Ifitm3 had no effect in this culture 
system (Fig. 6, G and H).
We then established a BCR-ABL1-rtTA3-shIkaros 
B-ALL cell line through continuous culture (∼3 wk) on OP9 
cells. Infection with TRM PV vectors and 3 d of Dox treat-
ment induced dsRed/shRNA, at which point cells expressing 
the Ctnnd1.3465 shRNA showed a minor decrease in via-
bility (Fig. S5, F and G). 50,000 viable GFPhidsRedhi B-ALL 
cells were then sorted and replated on stromal support for an 
additional 7 d in the presence of Dox to maintain shRNA 
expression and target gene knockdown (Figs. 6 F and S5, H 
and I). As anticipated, Myc knockdown decreased B-ALL 
proliferation and viability relative to negative control cells 
expressing an shRNA-targeting Renilla luciferase (Fig. 6 I). 
Notably, both Ctnnd1 shRNAs also inhibited B-ALL cell ex-
pansion (associated with loss of viability for the Ctnnd1.3465 
shRNA), but with no significant change in cell cycle (Figs. 6 
I and S5, H and I). Previous studies have implicated Ctnnd1 
in the regulation of Wnt pathway target genes, including the 
proliferative drivers Myc and Ccnd1/Cyclin D1 (Daniel and 
Reynolds, 1999; van Roy and McCrea, 2005; Schackmann et 
al., 2013). Although we observed a modest decrease in Myc 
expression in Ctnnd1.3465 shRNA cells, Ccnd1 expression 
was not affected by Ctnnd1 knockdown (Fig. 6 I and S5 J). 
Although Ifitm3 and Emp1 knockdown did not reduce over-
all cell numbers in these assays, Ifitm3 suppression modestly 
decreased B-ALL viability associated with Myc and Ccnd1 
down-regulation (Figs. 6 I and S5 J). Together, these experi-
ments demonstrate that Ctnnd1 promotes growth and viabil-
ity of Ikaros-kd BCR-ABL1+ B-ALL cells ex vivo.
dIScuSSIon
Disruption of genes encoding hematopoietic transcription 
factors occurs in the majority of B-ALL cases; however, iden-
tifying transcription factor target genes relevant to tumor sup-
pression remains a major challenge. In this study, we have taken 
a unique approach to identifying high-confidence IKA ROS- 
regulated genes in B-ALL based on an integrated analysis of 
gene expression profiles accompanying IKA ROS loss in mu-
rine and human disease. This approach includes customary 
comparisons of IKA ROS-deficient and IKA ROS-proficient 
samples in multiple primary murine B-ALL models and two 
independent human B-ALL cohorts, but importantly also in-
corporates gene expression profiling of murine B-ALL upon 
dynamic restoration of endogenous Ikaros in vivo. Including 
this transcriptional filter mutes the influence of co-occur-
ring oncogenic lesions, cell type differences, or adaptive gene 
expression changes associated with steady-state Ikaros loss, 
and enriches for genes particularly sensitive to Ikaros status 
in established disease.
In the novel mouse models of BCR-ABL1+ B-ALL 
described here, RNAi-based Ikaros knockdown significantly 
accelerates leukemogenesis, consistent with previous stud-
ies using Ikaros germline mutant mice (Virely et al., 2010; 
Schjerven et al., 2013; Churchman et al., 2015). By exploiting 
the reversibility of RNAi, we further demonstrate that Ikaros-
low B-ALL undergoes sustained and in some cases indefinite 
regression when Ikaros function is re-engaged. The sensi-
tivity of established leukemia to Ikaros restoration provides 
proof-of-principle for therapeutic approaches that engage 
components of the Ikaros-regulated transcriptome. In addi-
tion, the fact that B-ALL can be eradicated by Ikaros resto-
ration despite ongoing BCR-ABL1 activity implicates Ikaros 
in pathways that cooperate with BCR-ABL1 during disease 
pathogenesis in addition to providing BCR-ABL1–indepen-
dent functions in established disease. BCR-ABL1–indepen-
dent functions of IKA ROS also appear likely in pediatric 
BCR-ABL1+ B-ALL, where IKZF1 mutation/deletion is as-
sociated with poor clinical response to standard therapies and 
the BCR-ABL1 inhibitor imatinib (van der Veer et al., 2014).
The B-ALL mouse models described here and else-
where (Virely et al., 2010; Schjerven et al., 2013; Churchman 
et al., 2015) functionally recapitulate the high rates of IKZF1 
alteration observed in human BCR-ABL1+ B-ALL, suggest-
ing that the transcriptomic changes underlying this genetic 
interaction may be evolutionarily conserved. We approached 
this possibility by applying stringent statistical thresholds 
to identify ∼400 IKA ROS-regulated genes common to 
cells infected with TRM PV vectors expressing the indicated shRNAs. Cells were Dox treated for 4 d and GFP+dsRed+ cells were isolated by FACS. Mean 
± SEM for three independent experiments. (E) Western blots of Ctnnd1 expression in splenic tumor cells harvested from two independent tet-on competent 
primary B-ALL transplant recipients infected with TRM PV vectors expressing shRen.713 or two different Ctnnd1 shRNAs as indicated. Before organ harvest, 
mice were Dox treated for 4 d and GFP+dsRed+ cells were isolated by FACS. Actin is a loading control. (F) Schematic of the culture strategy for (G–I) below. 
(G) Representative dsRed and GFP flow cytometry of primary tet-on competent Ikaros-kd BCR-ABL1+ B-ALL cells (viable CD19+IgM– cells) after ex vivo 
infection with TRM PV vectors, 4 d Dox treatment, and plating at a 1:1 ratio of uninfected (CD19+GFP–mCherry–) and infected (CD19+GFP+mCherry+) B-ALL 
cells as shown in F. (H) Proportion of dsRed+ B-ALL cells within the viable CD19+IgM– gate as described in G. Mean ± SEM for four experiments in two 
independent primary tet-on–competent leukemias. (I) Analysis of an established cell line derived from continuous passage of a primary tet-on–competent 
Ikaros-kd BCR-ABL1+ B-ALL, infected with indicated TRM PV-shRNAs as shown in F. After 3 d of Dox treatment on OP9 stroma, 50,000 sorted GFP+dsRed+ 
B-ALL cells were replated in Dox on OP9 stroma for a further 7 d before analysis. Plots show overall cell counts (left), the proportion of viable DAPI– cells 
(middle), and RT-qPCR analysis of Myc expression (right). Mean ± SEM, n = 5 independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001, relative to 
Ren.713, unpaired Student’s t test.
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two independent human B-ALL sample cohorts compris-
ing multiple disease subtypes, then intersecting them with 
genes that behave concordantly in our mouse B-ALL mod-
els. This unbiased, cross-species analysis yields 13 conserved 
IKA ROS-regulated genes in B-ALL. Of particular interest are 
the nine conserved IKA ROS-repressed genes, which are all 
directly bound by IKA ROS and may represent disease driv-
ers and therapeutic targets in IKZF1-deficient disease. High 
expression of 6 of these genes (CTN ND1, EMP1, FXYD6, 
IFI TM3, AGAP3, and ITP RIPL2) also individually predict 
inferior event-free survival in both patient cohorts, suggesting 
a potential role in B-ALL therapy resistance.
Recent studies in mice show that Ikaros mutant B cell 
progenitors and B-ALL cells rely on cell–cell adhesion for 
survival (Joshi et al., 2014; Churchman et al., 2015). Dis-
rupting adhesion may be a rational approach to treating 
Ikaros mutant B-ALL (Joshi et al., 2014; Churchman et al., 
2015), however the adhesive mechanisms of Ikaros mutant 
cells remain poorly understood. Notably, of the 9 con-
served IKA ROS-repressed genes identified in our study, 
IFI TM3, EMP1, and CTN ND1 all encode transmem-
brane or membrane-associated proteins with established 
roles in cell–cell adhesion. IFI TM3 encodes interferon in-
ducible transmembrane protein 3, required for germ cell 
migration (Tanaka et al., 2005), which plays an essential 
role in cellular resistance to viral infection (Everitt et al., 
2012) and promotes colon cancer pathogenesis and me-
tastasis (Andreu et al., 2006; Li et al., 2011). Of note, IFI 
TM3 was recently implicated in B-ALL pathogenesis for 
the first time, emerging as a central mediator of B-ALL 
proliferation and survival by promoting CD19-mediated 
PI3K–AKT signaling (Lee et al., 2015). EMP1 encodes 
epithelial membrane protein 1, which in epithelial cells 
resides in tight junctions (Durgan et al., 2015). EMP1 was 
also recently implicated in B-ALL, identified among genes 
with high expression in B-ALL samples that are resistant 
to therapeutic glucocorticoids (Ariës et al., 2014). In that 
study, elevated EMP1 confers glucocorticoid resistance 
and enhanced adhesion of ALL cell lines in vitro, and 
is associated with inferior event–free survival of B-ALL 
patients (Ariës et al., 2014). Hence, our identification 
of EMP1 and IFI TM3 as conserved IKA ROS-repressed 
genes suggests novel mechanisms whereby disruption 
of IKZF1 promotes B-ALL development and treatment 
resistance. EMP1 is also unique among conserved IKA 
ROS-regulated genes in that its high expression pre-
dicts poor EFS within the IKZF1 wild-type subset of 
both patient cohorts, suggesting an additional, IKA ROS- 
independent influence on disease outcome.
Along with EMP1 and IFI TM3, CTN ND1 is nota-
ble among conserved IKA ROS-repressed genes for several 
reasons. Ctnnd1 is the most significantly down-regulated 
gene upon Ikaros restoration in our murine B-ALL model, 
displaying rapid and sustained mRNA and protein repres-
sion. In the DCOG/COA LL patient cohort, CTN ND1 is 
the top-ranked up-regulated gene in IKZF1-deleted ver-
sus IKZF1 wild-type disease, and its elevated expression is 
a more powerful predictor of poor EFS than IKZF1 dele-
tion. Our identification of CTN ND1 as a novel and direct 
IKA ROS-repressed gene provides a mechanistic basis for 
previous studies listing CTN ND1 among genes highly 
expressed in IKZF1-deleted versus IKZF1 wild-type, 
Ph-negative B-ALL (Vitanza et al., 2014), and among 
genes highly expressed in Ph+ B-ALL (a subtype en-
riched for IKZF1 alterations; Mullighan et al., 2008a) 
versus other B-ALL subtypes (Juric et al., 2007). Impor-
tantly, we find that high CTN ND1 expression is associ-
ated with inferior EFS, even within molecular subgroups 
of the DCOG/COA LL cohort (including those defined 
by IKZF1 status or combined BCR-ABL1/BCR-ABL1-
like status), suggesting that high CTN ND1 expression in-
fluences B-ALL outcome regardless of whether it occurs 
as a result of IKZF1 deletion.
Using a novel tet-on competent murine B-ALL model 
driven by combined BCR-ABL1 expression and Ikaros 
knockdown, we have demonstrated a novel requirement 
for Ctnnd1 in leukemia maintenance. In epithelial cells, the 
Ctnnd1 gene product P120-catenin regulates cell–cell ad-
hesion by direct stabilization of E-cadherin (Ireton et al., 
2002; Davis et al., 2003), but in many cell types, it also ac-
tivates β-catenin (Ctnnb1) by directly interfering with the 
transcriptional repressor Kaiso in the nucleus (Daniel and 
Reynolds, 1999; van Roy and McCrea, 2005; Schackmann et 
al., 2013). We have shown for the first time that mouse and 
human B-ALL cells predominantly express Ctnnd1/CTN 
ND1 mRNA splice forms predicted to encode nuclear local-
ized P120-catenin. Although it is tempting to speculate that 
P120-catenin could contribute β-catenin activation, which 
has been implicated in acute leukemia self-renewal and re-
lapse (Wang et al., 2010; Dandekar et al., 2014; Giambra et 
al., 2015), we did not observe consistent down-regulation 
of the β-catenin target genes Myc and Ccnd1 upon Ctnnd1 
knockdown in our B-ALL model system. Hence the mech-
anism whereby P120-catenin promotes B-ALL maintenance 
remains to be determined.
In summary, we have taken advantage of novel mouse 
models and recent major advances in the molecular anno-
tation of large B-ALL patient cohorts to perform the first 
cross-species comparison of IKA ROS-regulated genes in 
B-ALL. Among gene products with conserved, abnormally 
high expression in IKZF1-mutated/deleted B-ALL are 
EMP1 and IFI TM3, both recently implicated in B-ALL 
pathogenesis and therapy resistance, and CTN ND1, for 
which we demonstrate a novel role in B-ALL mainte-
nance. Elevated CTN ND1, EMP1, or IFI TM3 expression 
in B-ALL is associated with increased risk of relapse in 2 
independent patient cohorts. These findings suggest novel 
mechanisms whereby IKZF1 mutations confer poor prog-
nosis in B-ALL and identify potential new therapeutic tar-
gets in high risk disease.
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transgenic mice
TREtight-GFP-shIkaros.4056 and TREtight-GFP-shRe-
nilla.713 mice were previously described (Witkowski et al., 
2015). TRE-GFP-shIkaros.2709 transgenic mice harbor a 
different shRNA (Ikaros.2709 not Ikaros.4056) and a differ-
ent tet-regulatable promoter (TRE not TREtight) that af-
fords improved shRNA expression in B cell progenitors, and 
were generated using previously described protocols (Prems-
rirut et al., 2011). BCR-ABL1P190 and Vav-tTA transgenic 
mice were described previously (Heisterkamp et al., 1990; 
Kim et al., 2007). TRE-GFP-shIkaros.4056 transgenic mice 
(Witkowski et al., 2015) and TRE-GFP-shIkaros.2709 trans-
genic mice were PCR genotyped using a common forward 
primer that anneals to the endogenous Col1a1 locus (5′-AAT 
CAT CCC AGG TGC ACA GCA TTG CGG-3′) and a reverse 
primer that either anneals to the Col1a1 locus (5′-CTT TGA 
GGG CTC ATG AAC CTC CCA GG-3′) to amplify a 238-bp 
wild-type allele product, or anneals to the transgene SAdpA 
cassette (5′-ATC AAG GAA ACC CTG GAC TAC TGCG-3′) 
to amplify a 300-bp transgene product. PCR conditions were 
95°C for 5 min, 35 × (95°C for 40 s, 62°C for 45 s, and 72°C 
for 60 s), and 72°C for 60 s. The BCR-ABL1P190 transgene 
was detected using PCR primers 5′-AGA GAT CAA ACA 
CCC TAA CCT-3′ and 5′-CCA AAG CCA TAC TCC AAA 
TGC-3′, using PCR conditions 95°C 6’, 35 × (95°C for 
30 s, 55°C for 40 s, and 72°C for 40 s), 72°C 60”. The Vav-
tTA transgene was detected as described previously (Liu et al., 
2014). Mice were on an inbred C57BL6/J background apart 
from Vav-tTA mice, which were on an FVB/N background. 
Doxycycline (Dox; Sigma-Aldrich) was administered in the 
diet at 600 mg/kg food (Specialty Feeds). All mouse exper-
iments were approved by the Walter and Eliza Hall Institute 
Animal Ethics Committee.
retroviral infection
We adapted an established protocol (Li et al., 1999) to pref-
erentially drive B-ALL rather than CML upon retroviral ex-
pression of BCR-ABL1P190. Bone marrow harvested from 
both femurs of 4-wk-old CD45.2+ mice was resuspended in 
ice-cold PBS, centrifuged at 1,500 rpm for 5 min at 4°C, 
and red blood cells were briefly lysed using red cell lysis buf-
fer. Cells were resuspended in IMDM supplemented with 
15% FCS, 10 ng/ml mIL-7 (PeproTech), 100 ng/ml mSCF 
(PeproTech), 50 ng/ml Flt3L and TPO (in-house), and 2 mM 
l-glutamine (Life Technologies), and incubated at 37°C, 
10% CO2 overnight. Cells were then reresuspended in fresh 
media at 2 × 106 cells/ml. Retronectin-coated, non–tissue 
culture treated plates were coated with 1  ml of MSCV-
BCR-ABL1-IRES-Luc2 and MSCV-IRES-tTA retrovirus. 
Viral supernatant was aspirated, and 1 ml of bone marrow 
cell suspension was plated per well followed by incubation 
cells at 37°C, 10% CO2 overnight. Infected cells were then 
injected intravenously into lethally irradiated CD45.2+ re-
cipient mice. Similar methods were used to generate tet-on 
competent B-ALL; however, bone marrow was co-infected 
with MSCV-BCR-ABL1-IRES-Luc2 and MSCV-rtTA3- 
shIkaros.4056 before transplant.
Leukemia cell culture and Western blotting
OP9 stromal feeder cells were cultured in IMDM supple-
mented with 10% FBS, 100 µg/ml streptomycin, 100 U/ml 
penicillin, 100 µM l-glutamine, and 50 µM β-mercaptoetha-
nol and grown at 37°C in 10% CO2. B-ALL tumor cells were 
cultured on an OP9 layer in media conditioned with 1ng/
µl IL-7 (PeproTech). For tet-on–competent B-ALL trans-
duction, 5 × 106 freshly harvested secondary leukemic spleen 
cells were spin-infected at 1,200 rpm at 22°C onto TRM 
PV-shRNA retrovirus-coated plates for 2 h. After centrifu-
gation, cells were incubated in medium for 6 h at 37°C in 
10% CO2 and plated onto OP9 stroma layer supplemented 
with Doxycycline and IL-7 (PeproTech). Sorted cells were 
cultured on OP9 in the presence of Doxycycline and ana-
lyzed by flow cytometry using BD Fortessa. Cell lysates were 
Western blotted with anti-Ikaros antibody E-20 (sc-9861; 
Santa Cruz Biotechnology, Inc.), anti–P120-catenin antibody 
98/pp120 (BD), and anti-actin antibody I-19 (sc-1616; Santa 
Cruz Biotechnology, Inc.).
Leukemia transplantation and flow cytometry analysis
Splenocytes (predominantly CD19+IgM– leukemia cells) from 
primary leukemic mice were injected into the tail vein of 
immunocompromised CD45.1+Rag1−/− recipient mice (106 
cells/mouse), which generally developed overt signs of leu-
kemia (e.g., anemia and splenomegaly) after ∼2–3 wk. Sin-
gle-cell suspensions were prepared from bone marrow, spleen, 
and peripheral blood of secondary leukemic mice. After red 
blood cell lysis, cells were stained with APC-conjugated an-
ti-IgM (eBioscience), PE-Cy7–conjugated anti-CD19 (BD), 
Alexa Fluor700–conjugated anti-CD45.2 (WEHI), bio-
tin-conjugated CD43 (BD), PE-conjugated CD24 (BD), and 
PerCP-Cy5.5–conjugated Streptavidin. Stained cells were ana-
lyzed on a fluorescence-activated cell sorter (Fortessa; BD). To 
assess viability, cells were stained with Fluoro-Gold (Sigma-Al-
drich). For OP9 co-culture, cells were harvested and removed 
from the stromal layer before antibody staining. Stat5 activation 
(pStat5) analysis was performed as previously described (Trem-
blay et al., 2016) on single cell spleen or bone marrow suspen-
sions stained with antibodies against mouse CD45.1 (A20) and 
CD45.2 (104; BD). Cells were fixed in 4% paraformaldehyde 
for 10 min at 4°C in the dark, washed twice with 2% FCS in 
PBS, and permeabilized in pre-chilled Phosflow Perm Buffer 
III (BD) for 30 min at 4°C. Permeabilized cells were washed 
in 2% FCS in PBS and stained overnight at 4°C using rabbit 
anti–mouse phospho-Stat5 (Tyr694) antibody (#9351; Cell 
Signaling Technology). Stained cells were washed twice and 
incubated in 2% FCS in PBS with donkey Alexa Fluor 546–
conjugated anti–rabbit secondary antibody (A10040; Molecu-
lar Probes) for 1 h on ice. Cells were washed twice in ice-cold 
PBS, and flow analysis was performed using a LSR II cytometer.
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Gene expression analysis
RNA was extracted from FACS-sorted CD45+CD19+IgM– 
tumor cells using an RNeasy kit (QIA GEN, CA). For 
RT-qPCR analysis, 4.5 µg of total RNA was converted to 
cDNA, 1  µl of which was used in triplicate 10  µl SYBR 
Green (Roche) PCR reactions using a LightCycler 480 In-
strument (Roche). Primer sequences (5′-3′): Hprt-FWD 
5′-CAG TAC AGC CCC AAA ATG GT-3′; Hprt-REV 5′-
CAA GGG CAT ATC CAA CAA CA-3′; Ikzf1-FWD 5′-CAA 
TGT CGC CAA ACG TAA GA-3′; Ikzf1-REV 5′-GTT GAT 
GGC ATT GTT GAT GG-3′; Ctnnd1-FWD 5′-CAG GAC 
AGA TTG TGG AAA CCTA-3′; Ctnnd1-REV 5′-GCT GTA 
CTG TCC GAG TTG TCAT-3′; Emp1-FWD 5′-GTT GGT 
GCT ACT GGC TGG TC-3′; Emp1-REV 5′-TAC CAC CAG 
TGC AGT TCT TCC-3′; Ifitm3-FWD 5′-ATG TGG TCT 
GGT CCC TGT TC-3′; Ifitm3-REV 5′-CTT AGC AGT 
GGA GGC GTA GG-3′; Myc-FWD 5′-ACA GGA CTC CCC 
AGG CTC CG-3′; Myc-REV 5′-CGT GGC TGT CTG CGG 
GGT TT-3′; Ccnd1-FWD 5′-TCT GTG AGG AGC AGA 
AGT GC-3′; Ccnd1-REV 5′-CTT AGA GGC CAC GAA 
CAT GC-3′. Ct values were calculated using LightCycler 480 
software and relative mRNA expression levels determined 
using Standard Curve Method.
For RNA-seq analysis, RNA-seq libraries were pre-
pared according to Illumina TruSeq RNA preparation pro-
tocols. Single-index RNA adapters were ligated to RNA 
samples run on the Illumina HiSeq 2000 sequencing plat-
form, whereas dual-indexed sequencing adapters were ligated 
to samples for the Illumina Next-Seq 500 platform. 26 RNA 
samples were sequenced in three different batches. Eight sam-
ples from tumors B891, B1030, B1040, and B1044 (retroviral 
system) produced between 2–12 million single-end 100-
bp reads on Illumina HiSeq. 6 samples from tumors B011, 
B031, and B035 (transgenic system) produced 14–17 million 
paired-end 100 bp reads on Illumina HiSeq. 12 samples from 
tumor B005, B014, B027, B031, B038, and B041 (transgenic 
system) produced 5–7 million paired-end 76-bp reads on Il-
lumina NextSeq with counts from four technical replicates 
summed for each sample. Samples from tumor B1030, B011, 
B005, and B041 contain two controls, one at day 0 and the 
other at day 3 Dox treatment. For the remaining tumors, each 
has an Ikaros knockdown sample and an Ikaros restoration 
sample after Dox treatment.
Bioinformatic analysis
RNA sequence reads were mapped to the mouse genome 
(mm10) using the subread aligner (Liao et al., 2013) imple-
mented in the Rsubread software package. Read counts for 
each Entrez Gene were obtained using featureCounts (Liao 
et al., 2014) and its inbuilt mm10 annotation. Sequence reads 
and counts are available from Gene Expression Omnibus 
under accession no. GSE75976.
Statistical analysis used the edgeR (Robinson et al., 
2010) and limma (Ritchie et al., 2015) software packages. 
Genes were filtered as not expressed if they failed to achieve 
0.5 read counts per million (cpm) in at least four samples. 
Genes from chromosome Y and the gene Xist were filtered 
out to avoid gender effects. Predicted genes, immunoglob-
ulin genes, mitochondrial genes, and genes without official 
gene symbols were also filtered. Trimmed Mean of M-values 
(TMM) scale normalization (Robinson and Oshlack, 2010) 
was applied and read counts were transformed to log2-cpm 
with a prior count of 1 using edgeR’s cpm function. Linear 
models were used to test for expression differences between 
Ikaros restoration versus Ikaros knockdown and between 
Ikaros knockdown versus control at day 0 while adjusting 
for batch effects. An extra surrogate variable was estimated to 
adjust for unwanted nuisance technical effects by performing 
a singular value decomposition of the residuals, with empha-
sis on highly variable genes. Empirical array quality weights 
were estimated to allow for differences in quality between 
the RNA samples (Ritchie et al., 2006). Each tumor was 
treated as a random block, allowing for correlation between 
the two samples from the same tumor (Smyth et al., 2005). 
Differential expression were assessed using empirical Bayes 
moderated t-statistics (Smyth, 2004), allowing for an abun-
dance trend in the standard errors and for robust estimation 
of the Bayesian hyperparameters. The underlying biological 
correlation between the Acceleration and Restoration ex-
pression profiles was estimated using limma’s genas function 
(Ritchie et al., 2015). This method corrects for the techni-
cal correlation that arises from sharing controlling samples 
between the two profiles.
To identify conserved IKA ROS-repressed and -acti-
vated genes, human gene symbols from the US cohort were 
mapped to Entrez Gene IDs using NCBI annotation and 
probeset IDs from the DCOG/COA LL cohort were mapped 
to Entrez Gene IDs using Affymetrix annotation. Murine 
gene lists were mapped to human Entrez Gene IDs using 
the Jackson Laboratory mouse-human ortholog table and the 
NCBI mouse-human homologue table. Gene ontology anal-
ysis used limma’s goana function. Tumors with relapse samples 
were analyzed separately for Fig. S2. Log2 reads per kilobase 
per million reads (log2-RPKM) were computed using edg-
eR’s rpkm function with prior count of 1. The heat map was 
created using the heatmap.2 function in the gplots package.
IKA ROS ChIP in human B-ALL cells as de-
tailed in Schjerven et al. (2016) identified 11,446 human 
IKA ROS-bound genes corresponding to 11,525 mouse 
homologues. Overlap analysis identified IKA ROS- 
regulated genes bound by IKA ROS.
B-ALL patient cohort analysis
US cohort patients were from the St. Jude Children’s Re-
search Hospital Total XV and Total XVI protocols, the 
COG P9906 high-risk B-ALL study, the COG AALL0232 
high-risk ALL study, the ECOG E2993 trial, the MD An-
derson Cancer Centre protocols, and the Alliance (Cancer 
and Leukemia Group B) protocols C19802 and C10102. 
Single-nucleotide polymorphism (SNP) 6.0 microar-
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ray analysis (Affymetrix) and RNA sequencing (Illumina 
Tru-seq) were performed as previously described (Rob-
erts et al., 2014). Event-free survival was estimated using 
Kaplan-Meier, with Peto’s estimator of standard deviation 
and the log-rank test. An event was defined as a failure to 
achieve remission, a relapse after remission, or the develop-
ment of a second malignancy. Analysis was performed using 
Prism software (GraphPad), R software, and SAS software 
version 9.1.2 (SAS Institute).
The DCOG/COA LL cohort comprises children with 
newly diagnosed BCP-ALL enrolled in consecutive Dutch 
Childhood Oncology Group trials (DCOG ALL-8, ALL-9, and 
ALL-10) and German Cooperative ALL trials (COA LL 06–97 
and 07–03). This combined patient cohort was described previ-
ously (Den Boer et al., 2009; van der Veer et al., 2013). Event-
free survival included relapse, secondary malignancy or death as 
an event and was estimated using the actuarial Kaplan-Meier 
method and data were compared using the log-rank test. EFS was 
estimated in R version 3.0.1 using the package survival 2.37–4.
online supplemental material
Figs. S1 and S2 describe generation of primary and relapsed 
mouse B-ALL models. Figs. S3 and S4 detail human B-ALL 
cohort data. Fig. S5 documents Ikaros target gene expres-
sion in mouse B-ALL models and CTN ND1 splicing in 
B-ALL. Tables S1–S3 list murine B-ALL Acceleration, Res-
toration, and Ikaros-regulated genes. Tables S4 and S5 in-
clude gene ontology and KEGG analysis. Tables S6 and S7 
list human B-ALL IKA ROS-regulated genes. Table S8 lists 
IKA ROS-regulated genes common to both human B-ALL 
cohorts. Tables S1–S8 are available as Excel Files.
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